journal article·2018Open access

Photostability of Risperidone in Tablets

Yuki Fujisawa, Yoshiteru Takahashi, Reiko Teraoka, Shuji Kitagawa

KONA Powder and Particle Journal· Volume 35· Issue 0

Abstract

The purpose of this study is to evaluate the photostabilization mechanism of risperidone tablets. Risperidone is widely used for sensory integration disorder. It is formulated as tablets, orally disintegrating tablets, fine granules, oral solutions, and intramuscular injections. We found that risperidone was unstable in tablets and generated oxidized products. Formation of the oxidized product R5 was promoted in the presence of hydroxypropylcellulose by photoirradiation. On the other hand, photostability improved greatly when carmellose (CMC) or carmellose calcium (CMC-Ca) was used as a disintegrant. Since CMC and CMC-Ca are acidic substances, the photostability of tablets may have been affected by pH. Therefore, the effects of different pHs were examined. Risperidone was dissolved in methanol and the buffer (in the presence or absence of hydroxypropylcellulose) at different pHs (1.2, 3.0, 4.0, 5.0, and 6.8) was added. The photodegradation of risperidone was not observed at less than pH 3.0 in the presence of hydroxypropylcellulose, and low pHs improved the photostability of risperidone. On the other hand, risperidone solution without hydroxypropylcellulose was stable at all pH values. Therefore, risperidone was photochemically oxidized in the presence of hydroxypropylcellulose at high pHs.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Drug Solubulity and Delivery Systems · Analytical Chemistry and Chromatography · Analytical Methods in Pharmaceuticals

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Pharmaceutical Technology Center, Sawai Pharmaceutical Co., Ltd., Japan

Laboratory of Pharmaceutical Technology, Kobe Pharmaceutical University, Japan

References (22)

Show source-provided references
1. Alparone A., Spectroscopic properties of neuroleptics: IR and Raman spectra of Risperidone (Risperdal) and of its mono- and di-protonated forms, Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 81 (2011) 631–639.10.1016/j.saa.2011.06.065 ↗
2. Berendt R.T., Sperger D.M., Isbester P.K., Munson E.J., Solid-state NMR spectroscopy in pharmaceutical research and analysis, TrAC Trends in Analytical Chemistry, 25 (2006) 977–984.10.1016/j.trac.2006.07.006 ↗
3. Berus P., Gartner A., Mlakar A., Puncuh K.A., Vrecer F., Preparation of a stable oral solution with risperidone, European Journal of Pharmaceutical Sciences, 25S1 (2005) S57–S58.
4. Bharathi Ch., Chary D.K., Kumar M.S., Shankar R., Handa V.K., Dandala R., Naidu A., Identification, isolation and characterization of potential degradation product in risperidone tablets, Journal of Pharmaceutical and Biomedical Analysis, 46 (2008) 165–169.10.1016/j.jpba.2007.08.008 ↗
5. Bhatu P.B., Atish S.M., The technologies used for developing orally disintegrating tablets: A review, Acta Pharmaceutica, 61 (2011) 117–139.10.2478/v10007-011-0020-8 ↗
6. European Pharmacopoeia 8th Edition, Carmellose, Carmellose calcium, The European Directorate for the Quality of Medicines & HealthCare, 2014, pp. 1773–1774.
7. Germann D., Kurylo N., Han F., Risperidone, Chapter 8 in: Brittain H. (Eds.), Risperidone, Profiles of drug substances, excipients, and related methodology, Academic Press, 37, 2012, pp. 313–361.10.1016/B978-0-12-397220-0.00008-8 ↗
8. Grant S., Fitton A., Risperidone: A Review of its pharmacology and therapeutic potential in the treatment of schizophrenia, drugs, 48 (1994) 253–273.10.2165/00003495-199448020-00009 ↗
9. Iwakura Y., Fujisawa Y., Toyonaga N., Oral disintegrant tablet containing risperidone and method for producing the same, JP Patent, (2013) JP2013060392A.
10. Janssen P.A.J., The development of new antipsychotic drugs: Towards a new strategy in the management of chronic psychoses, Journal for Drugtherapy and Research, 12 (1987) 324–328
11. Janssen P.A.J., Niemegeers C.J.E., Awouters F., Schellekens K.H.L., Megens A.A.H.P. and Meert T.F., Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties, Journal of pharmacology and experimental therapeutics, 244–2 (1988) 685–693.
12. Karabas I., Orkoula M.G., Kontoyannis C.G., Analysis and stability of polymorphs in tablets: The case of Risperidone, Talanta, 71 (2007) 1382–1386.10.1016/j.talanta.2006.07.009 ↗
13. Kojima T., Onoue S., Katoh F., Teraoka R., Matsuda Y., Kitagawa S., Tsuhako M., Effect of spectroscopic properties of tamoxifen citrate polymorphs, International Journal of Pharmaceutics, 336 (2007) 346–351.10.1016/j.ijpharm.2006.12.025 ↗
14. Krochmal B., Diller D., Dolitzky B., Aronhime J., Preparation of risperidone, US Patent (2004) US6,750,341B2.
15. Leysen J.E., Gommeren W., Eens A., de Chaffoy de Courcelles D., Stoof J.C., Janssen P.A., Biochemical profile of risperidone, a new antipsychotic, The Journal of Pharmacology and Experimental Therapeutics, 247 (1988) 661–670.
16. Merck Index, 14th ed., Merck Research Laboratories, division of Merck & Co., Whitehouse Station, N.J., 2006, entry 8316, 1478.
17. Rahman Z., Zidan A.S., Khan M.A., Risperidone solid dispersion for orally disintegrating tablet: Its formulation design and non-destructive methods of evaluation, International Journal of Pharmaceutics, 400 (2010) 49–58.10.1016/j.ijpharm.2010.08.025 ↗
18. Suthar A.P., Dubey S.A., Patel S.R., Shah A.M., Determination of Risperidone and forced degradation behaviour by HPLC in tablet dosage form, International Journal of PharmTech Research, 1 (2009) 568–574.
19. Teraoka R., Konishi Y., Matsuda Y., Photochemical and oxidative degradation of the solid-state tretinoin tocoferil, Chemical & pharmaceutical bulletin, 49 (2001) 368–372.10.1248/cpb.49.368 ↗
20. Tomar R.S., Joseph T.J., Murthy A.S.R., Yadav D.V., Subbaiah G., Krishna Reddy K.V.S.R., Identification and characterization of major degradation products of risperidone in bulk drug and pharmaceutical dosage forms, Journal of Pharmaceutical and Biomedical Analysis, 36 (2004) 231–235.10.1016/j.jpba.2004.05.022 ↗
21. Tønnesen H.H., Formulation and stability testing of photolabile drugs, International Journal of Pharmaceutics, 225 (2001) 1–14.10.1016/S0378-5173(01)00746-3 ↗
22. Yasui-Furukori N., Hidestrand M., Spina E., Facciolá G., Scordo M.G., Tybring G., Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes, Drug Metabolism and Disposition, 29 (2001) 1263–1268.